Literature DB >> 17190729

A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy.

Kouichi Tamura1, Yuko Tsurumi, Masashi Sakai, Yutaka Tanaka, Yasuko Okano, Junji Yamauchi, Tomoaki Ishigami, Minoru Kihara, Nobuhito Hirawa, Yoshiyuki Toya, Machiko Yabana, Yasuo Tokita, Toshimasa Ohnishi, Satoshi Umemura.   

Abstract

Evidence suggests a relationship between short-term blood pressure (BP) variability and cardiovascular target-organ damage. Although a blunted nocturnal decrease in BP and reduced heart rate variability have been shown to be associated with cardiovascular morbidity in diabetic patients, little information is available on short-term BP variability. In this study, short-term BP variability was assessed in 36 subjects with type 2 diabetes and overt nephropathy who underwent ambulatory BP monitoring, and the factors that correlated with short-term BP variability were examined. The incidence of coronary artery disease (CAD) was significantly greater in the patients with increased 24-h systolic BP variability (67% versus 11%; p < 0.0005), while that of cerebrovascular disease was not significantly affected (61% versus 50%). Multiple stepwise regression analysis revealed that serum cholesterol (cholesterol) and plasma norepinephrine (p-NE) were significant and independent contributors to nighttime systolic BP variability (partial R2 = 0.490, p < 0.001; partial R2 = 0.470, p < 0.001) and demonstrated that body mass index and p-NE were primary determinants of nighttime diastolic BP variability (partial R2 = 0.539, p < 0.0005; partial R2 = 0.304, p < 0.05). Diabetic nephropathy patients with CAD had significantly increased daytime systolic (17.8 mmHg versus 13.1 mmHg, p < 0.0005), nighttime systolic (17.4 mmHg versus 10.5 mmHg, p < 0.0001), and nighttime diastolic (10.4 mmHg versus 7.2 mmHg, p < 0.05) BP variability. Furthermore, logistic regression analysis demonstrated that nighttime systolic BP variability was an independent risk factor for CAD (odds ratio 3.13 [95% CI 1.02-9.61]; p < 0.05). The increase in nighttime BP variability is associated with a proportional sympathetic activation in diabetic nephropathy. Elevated short-term BP variability combined with relative sympathetic prevalence during the night might represent an important risk factor for cardiovascular events in the diabetic population.

Entities:  

Mesh:

Year:  2007        PMID: 17190729     DOI: 10.1080/10641960601096760

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  17 in total

1.  Utility and feasibility of a new programmable home blood pressure monitoring device for the assessment of nighttime blood pressure.

Authors:  Hisako Ushio; Tomoaki Ishigami; Naomi Araki; Shintaro Minegishi; Koichi Tamura; Yasuko Okano; Kazuaki Uchino; Osamu Tochikubo; Satoshi Umemura
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

Review 2.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

3.  Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension.

Authors:  Kazuo Eguchi; Satoshi Hoshide; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2012-06-28       Impact factor: 2.689

Review 4.  Ambulatory blood pressure monitoring in the prediction and prevention of coronary heart disease.

Authors:  Yuan-Yuan Kang; Yan Li; Ji-Guang Wang
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

5.  Cardiovascular and autonomic phenotype of db/db diabetic mice.

Authors:  Danielle Senador; Keerthy Kanakamedala; Maria Claudia Irigoyen; Mariana Morris; Khalid M Elased
Journal:  Exp Physiol       Date:  2009-02-13       Impact factor: 2.969

6.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

7.  Influence of HbA1c on short-term blood pressure variability in type 2 diabetic patients with diabetic nephropathy.

Authors:  Fang Liu; Min Wu; Yan-huan Feng; Hui Zhong; Tian-lei Cui; You-qun Huang; Ya-ping Liang; Yong-shu Diao; Li Zang; Ling Li; Jing Zang; Hong-yu Qiu; Song-min Huang; Ping Fu
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

8.  Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Authors:  E Ritz; G C Viberti; L M Ruilope; A J Rabelink; J L Izzo; S Katayama; S Ito; A Mimran; J Menne; L C Rump; A Januszewicz; H Haller
Journal:  Diabetologia       Date:  2009-10-30       Impact factor: 10.122

9.  Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes.

Authors:  Kazuo Eguchi; Joji Ishikawa; Satoshi Hoshide; Thomas G Pickering; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2008-10-02       Impact factor: 2.689

Review 10.  Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes?

Authors:  Gianfranco Parati; Grzegorz Bilo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.